contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


biohit-sustainability-turnaround-being-tested

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Biohit operates in the medical technology sector. The company develops and manufactures laboratory equipment, consumables and diagnostic analysis systems adapted for research, healthcare and industrial laboratories. In addition to its main business, it offers technical support, maintenance and training services within the aforementioned field of work. The largest operations are conducted in the Nordic market. The company has its headquarters in Helsinki.

It should also be emphasized that L-cysteine is released from Acetium at a controlled rate locally in the stomach, while from other products, cysteine is intended to be absorbed from the small intestine into the bloodstream.

Very welcome news! However, as you noted, it probably doesn’t have much significance yet in terms of euros. In 2024, Biohit’s revenue from Finland was a total of 0.2 million euros.

Certainly not news that would cause a positive earnings warning, but for the first time in a long time, hangover + Acetium in a newspaper article. So no idea how much sales there needs to be for the wholesaler to run out.                  Helsingin Sanomat – 10 Dec 25              Alkoholi | Krapulan torjumiseen käytetty valmiste loppui tukusta    L-kysteiinin kysyntä on ollut kasvussa syksystä lähtien, kertovat apteekit.

Here are Antti’s comments regarding the recent Gastropanel study.  Biohit announced on Monday a new clinical study supporting the reliability of the GastroPanel test in ruling out the need for gastroscopy (stomach endoscopy). The news supports the company’s growth story and sales arguments, but does not cause immediate changes to our forecasts.                   Inderes              Uusi tutkimus GastroPanelin hyödyistä hoidon ohjauksessa - Inderes    Tutkimus tukee  tukee GastroPanel-testin luotettavuutta gastroskopian (mahalaukun tähystyksen) tarpeen poissulkemisessa

It’s great that this year marks 20 years since Gastropanel’s market entry, so it would be high time to make it big

At least according to that press release:  “Up to 90% of gastroscopies can be avoided when the GastroPanel® result is normal.”  And in the CEO’s own words (in the same release), the same claim: Biohit CEO Jussi Hahtela: “The results are very clear: when the GastroPanel® result is normal, gastroscopy is almost never needed. This is a significant turning point, enabling considerable cost savings and significantly shorter endoscopy queues.” Of course, one must remember that we’ve heard these kinds of statements from CEOs before (Biobone Substitutes, Faron Pharmaceuticals, e.g., about Traumakine, etc., etc.). This time, it all sounds absolutely wonderful. Of course, there’s always the possibility that years from now, we’ll realize that this company’s CEO’s statements should have been taken with a generous pinch of salt =). The main owner has been buying shares with a really big scoop lately, and insider purchases are generally considered a good sign. In my opinion, this news sounds, or at least has been made to sound, really good.

Do you assume that every test and treatment performed in hospitals is 100% accurate/successful? For example, over the past year, there have been many positive news stories from studies around the world where GastroPanel has been clearly proven to be a working solution.

Biohit

Biohit is focused on diagnostics of the gastrointestinal tract and health-promoting products. The company has shown the first signs of a turnaround after a long loss-making period.

<p>Biohit is focused on diagnostics of the gastrointestinal tract and health-promoting products. The company has shown the first signs of a turnaround after a long loss-making period. We feel a permanent turnaround of the result is likely thanks to new products, the renewed Chinese distribution agreement and effective implementation of the strategy. We believe that the development of new products and successful commercialization are key to the company's long-term success.</p> 

	2022	23e	24e
Revenue	11.0	11.3	12.6
growth-%	17.0 %	3.2 %	11.5 %
EBIT (adj.)	1.1	1.2	1.6
EBIT-% (adj.)	10.3 %	10.9 %	12.4 %
EPS (adj.)	0.04	0.07	0.09
Dividend	0.00	0.00	0.05
Dividend %			1.4 %
P/E (adj.)	39.3	53.8	40.6
EV/EBITDA	11.4	28.7	23.5

Biohit: Sustainability of turnaround being tested

Login required

Key Estimate Figures30.06.2023

Forum discussions